ES2989387T3 - Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb - Google Patents

Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb Download PDF

Info

Publication number
ES2989387T3
ES2989387T3 ES20733688T ES20733688T ES2989387T3 ES 2989387 T3 ES2989387 T3 ES 2989387T3 ES 20733688 T ES20733688 T ES 20733688T ES 20733688 T ES20733688 T ES 20733688T ES 2989387 T3 ES2989387 T3 ES 2989387T3
Authority
ES
Spain
Prior art keywords
met
femlo
mlo
hydroxy
dina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20733688T
Other languages
English (en)
Spanish (es)
Inventor
J Kent Barbay
Wenying Chai
Wendy Eccles
Michael D Hack
Aaron T Herrmann
William M Jones
Paul J Krawczuk
Kevin D Kreutter
Alec D Lebsack
Daniel J Pippel
Alexander R Rovira
Ronald L Wolin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2989387T3 publication Critical patent/ES2989387T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES20733688T 2019-05-31 2020-05-29 Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb Active ES2989387T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US201962907833P 2019-09-30 2019-09-30
PCT/EP2020/065024 WO2020239999A1 (en) 2019-05-31 2020-05-29 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

Publications (1)

Publication Number Publication Date
ES2989387T3 true ES2989387T3 (es) 2024-11-26

Family

ID=71108552

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20733688T Active ES2989387T3 (es) 2019-05-31 2020-05-29 Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb

Country Status (37)

Country Link
US (3) US11254673B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EP (2) EP3976597B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (2) JP7547387B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (1) KR20220027871A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN (2) CN118908957A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (1) AU2020282005A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BR (1) BR112021023796A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA3143350A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CL (1) CL2021003142A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CO (1) CO2021017838A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CR (1) CR20210587A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DK (1) DK3976597T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DO (1) DOP2021000244A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EC (1) ECSP21093623A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ES (1) ES2989387T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
FI (1) FI3976597T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HR (1) HRP20241352T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HU (1) HUE068694T2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IL (1) IL288387B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JO (1) JOP20210318A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LT (1) LT3976597T (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MA (1) MA56038B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MD (1) MD3976597T2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MX (1) MX2021014679A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MY (1) MY205653A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PE (1) PE20220768A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PH (1) PH12021553011A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PL (1) PL3976597T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PT (1) PT3976597T (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
RS (1) RS66105B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SA (1) SA521430960B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SG (1) SG11202112994WA (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SI (1) SI3976597T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SM (1) SMT202400418T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TW (2) TWI850390B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
UY (1) UY38721A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
WO (1) WO2020239999A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2989387T3 (es) * 2019-05-31 2024-11-26 Janssen Pharmaceutica Nv Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb
CN114502540A (zh) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 Tead抑制剂和其用途
US20250282785A1 (en) * 2022-05-11 2025-09-11 Janssen Pharmaceutica Nv Pyrrolidinone derivatives as inhibitors of nf kappa b inducing kinase
CN119604499A (zh) * 2022-05-11 2025-03-11 詹森药业有限公司 作为NFκB诱导激酶的抑制剂的吡咯烷酮衍生物
US20240279230A1 (en) 2022-12-22 2024-08-22 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
WO2025026901A1 (en) 2023-07-28 2025-02-06 Boehringer Ingelheim International Gmbh Process for the manufacture of a her2 inhibitor

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
US7592363B2 (en) * 2004-08-03 2009-09-22 Wyeth Indazoles
WO2006053277A2 (en) 2004-11-12 2006-05-18 Chippac, Inc. Wire bond interconnection
CA2728767A1 (en) 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
EP2686314A1 (en) 2011-03-16 2014-01-22 F.Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
HK1206024A1 (en) 2012-02-17 2015-12-31 F. Hoffmann-La Roche Ag Tricyclic compounds and methods of use therefor
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
MX2016002238A (es) 2013-08-22 2016-05-31 Hoffmann La Roche Alcoholes de alquilino y metodos de uso.
RU2016110021A (ru) * 2013-08-22 2017-09-27 Ф. Хоффманн-Ля Рош Аг Алкиниловые спирты и способы их применения
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
JP6603713B2 (ja) 2014-10-23 2019-11-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新規のチエノピリミジン誘導体
EP3209663B1 (en) 2014-10-23 2018-12-12 Janssen Pharmaceutica N.V. New pyrazolopyrimidine derivatives as nik inhibitors
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors
US9981962B2 (en) 2014-10-23 2018-05-29 Janssen Pharmaceutica Nv Pyrazole derivatives as NIK inhibitors
WO2016135163A1 (en) 2015-02-25 2016-09-01 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
ES2776658T3 (es) 2016-01-22 2020-07-31 Janssen Pharmaceutica Nv Nuevos derivados de cianoindolina con sustituyente heteroaromático de 6 miembros como inhibidores de NIK
WO2017125530A1 (en) 2016-01-22 2017-07-27 Janssen Pharmaceutica Nv New substituted cyanoindoline derivatives as nik inhibitors
EP3478675B1 (en) 2016-06-30 2020-04-22 Janssen Pharmaceutica NV Heteroaromatic derivatives as nik inhibitors
JP6936814B2 (ja) 2016-06-30 2021-09-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としてのシアノインドリン誘導体
WO2018037058A1 (en) * 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
CN109641894B (zh) 2016-08-24 2022-09-09 豪夫迈·罗氏有限公司 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法
MX2019014665A (es) 2017-07-06 2020-07-29 Janssen Pharmaceutica Nv Nuevos derivados de azaindolina sustituida como inhibidores de nik.
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途
CN114502540A (zh) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 Tead抑制剂和其用途
ES2989387T3 (es) * 2019-05-31 2024-11-26 Janssen Pharmaceutica Nv Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb
SG11202113129UA (en) 2019-05-31 2021-12-30 Ikena Oncology Inc Tead inhibitors and uses thereof
MX2021014115A (es) 2019-05-31 2021-12-10 Chiesi Farm Spa Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).
CA3139554A1 (en) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物

Also Published As

Publication number Publication date
RS66105B1 (sr) 2024-11-29
SMT202400418T1 (it) 2024-11-15
EP3976597A1 (en) 2022-04-06
IL288387A (en) 2022-01-01
AU2020282005A1 (en) 2021-12-23
CN114222737A (zh) 2022-03-22
HRP20241352T1 (hr) 2024-12-20
KR20220027871A (ko) 2022-03-08
MA56038B1 (fr) 2024-11-29
EP4467199A3 (en) 2025-03-05
JOP20210318A1 (ar) 2023-01-30
WO2020239999A1 (en) 2020-12-03
EP4467199A2 (en) 2024-11-27
US20230080834A1 (en) 2023-03-16
TWI850390B (zh) 2024-08-01
FI3976597T3 (fi) 2024-09-25
EP3976597B1 (en) 2024-08-28
JP2022534302A (ja) 2022-07-28
CN114222737B (zh) 2024-07-26
HUE068694T2 (hu) 2025-01-28
PH12021553011A1 (en) 2022-11-07
CA3143350A1 (en) 2020-12-03
MA56038A (fr) 2022-04-06
CO2021017838A2 (es) 2022-01-17
JP2024167319A (ja) 2024-12-03
MY205653A (en) 2024-11-02
DK3976597T3 (da) 2024-09-09
DOP2021000244A (es) 2022-04-18
CL2021003142A1 (es) 2022-08-19
MD3976597T2 (ro) 2025-01-31
SI3976597T1 (sl) 2024-11-29
CR20210587A (es) 2022-02-11
SG11202112994WA (en) 2021-12-30
MX2021014679A (es) 2022-04-06
PE20220768A1 (es) 2022-05-16
US20210300918A1 (en) 2021-09-30
UY38721A (es) 2020-11-30
SA521430960B1 (ar) 2024-11-12
IL288387B1 (en) 2025-09-01
PT3976597T (pt) 2024-10-22
US11254673B2 (en) 2022-02-22
TW202517638A (zh) 2025-05-01
LT3976597T (lt) 2024-10-10
BR112021023796A2 (pt) 2022-02-08
TW202110842A (zh) 2021-03-16
US11827634B2 (en) 2023-11-28
US20240199605A1 (en) 2024-06-20
JP7547387B2 (ja) 2024-09-09
ECSP21093623A (es) 2022-01-31
CN118908957A (zh) 2024-11-08
PL3976597T3 (pl) 2024-12-16

Similar Documents

Publication Publication Date Title
ES2989387T3 (es) Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb
ES2908412T3 (es) Derivados de piperidin-4-IL azetidina como inhibidores de JAK1
US8962596B2 (en) 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases
KR102516711B1 (ko) P2x7 조절제
ES2654288T3 (es) Moduladores de P2X7
BR112015032330B1 (pt) carboxamidas primárias como inibidores de bkt
TW201326173A (zh) ５，７－經取代之－咪唑并［１，２－ｃ］嘧啶
JP2011529920A (ja) ピリミジン化合物、組成物及び使用方法
EA032839B1 (ru) Конденсированные пентациклические производные имидазола
BR112020012651A2 (pt) compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
JP7413368B2 (ja) モノアシルグリセロールリパーゼ調節因子
CA2984307A1 (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
JP2023536920A (ja) 塩誘導性キナーゼ阻害剤
WO2020223590A1 (en) Modulators of trex1
WO2023283369A1 (en) Modulators of protein kinases
EA045720B1 (ru) НИЗКОМОЛЕКУЛЯРНЫЕ ИНГИБИТОРЫ NF-κB-ИНДУЦИРУЮЩЕЙ КИНАЗЫ
HK40071178A (en) Small molecule inhibitors of nf-kb inducing kinase
HK40071178B (en) Small molecule inhibitors of nf-kb inducing kinase
JP2025516597A (ja) Ｎｆカッパｂ誘導性キナーゼの阻害剤としてのピロリジノン誘導体
TW202527931A (zh) 視紫質的藥理校正劑及其用途
TW202513561A (zh) 治療發炎性疾病之方法